Detail akcie Immix Biopharma Rg online

Business Summary: Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Immix Biopharma Inc revenues was not reported. Net loss increased 16% to $11.2M. Higher net loss reflects Biotechnology & Medical Research segment loss increase of 11% to $11.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.38 to -$0.37.